DOD Bone Marrow Failure Investigator-Initiated Research Award | W81XWH 22 BMFRP IIRA

Opportunity Information: Apply for W81XWH 22 BMFRP IIRA

The DOD Bone Marrow Failure Investigator-Initiated Research Award (FY22 BMFRP IIRA; opportunity number W81XWH-22-BMFRP-IIRA) is a Department of Defense research funding opportunity administered through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It supports science and technology research and development projects focused on bone marrow failure (BMF) diseases, with an emphasis on work that can meaningfully move the field forward in terms of prevention, detection, diagnosis, and treatment. The program is open to a wide range of applicant organizations (eligibility is listed as unrestricted, with any limits spelled out in the full announcement), and it uses grant and cooperative agreement funding instruments. The original posting date was May 4, 2022, with an original application deadline of September 23, 2022, and the program anticipated making a small number of awards (listed as two expected awards in the source summary).

A key aspect of this opportunity is that it offers two distinct funding levels, each with a different purpose and set of expectations. Funding Level 1 (FL1) is designed to support investigator-initiated studies that build on promising ideas or key discoveries and push them further toward meaningful advances. FL1 projects can span basic research, translational research, and clinically oriented research, and they may include animal studies, studies using human anatomical substances, and research involving human subjects. FL1 can also include correlative studies tied to an existing clinical trial, such as analyses that help explain why certain patients respond, what biomarkers track with outcomes, or what measures could become future trial endpoints. Even so, FL1 funds cannot be used to run a clinical trial itself; the intent is to advance knowledge and readiness for improved care rather than to directly sponsor a trial under this mechanism. Multidisciplinary teamwork is encouraged to help applicants assemble the range of expertise and resources needed to complete ambitious projects.

Funding Level 2 (FL2) is more narrowly targeted and is intended to support IND-enabling work, meaning the practical, preclinical steps required to assemble a package suitable for submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration. The program explicitly recognizes that moving a potential therapy from lab promise to first-in-human evaluation is scientifically demanding and expensive, so FL2 emphasizes empirical, product-driven studies that generate the types of data regulators expect before clinical testing can begin. Examples of the required data domains include lead candidate characterization, formulation and stability, absorption/distribution/metabolism/excretion (ADME), dose-response, and toxicology. To keep FL2 focused on real advancement toward the clinic, applicants must name at least one and no more than three specific lead therapeutic candidates at the time of submission. Projects centered on library screening or general drug optimization are not considered responsive to FL2 because they do not represent a defined lead candidate being advanced through IND-enabling milestones. Like FL1, FL2 does not pay for clinical trials, but it is explicitly meant to generate the final preclinical evidence base that would allow a clinical trial to begin afterward. FL2 applications also have an additional alignment requirement: they must address the FY22 BMFRP focus area described as "Find effective BMF treatments and cures."

Across both funding levels, the opportunity highlights several features that strongly shape how applications are expected to be written and evaluated. First is impact: proposals should tackle a central, critical question or barrier in BMF research or clinical care, with the expectation that success would substantially improve how BMF diseases are prevented, detected, diagnosed, or treated. Second is translational potential: applicants are expected to explain how the work could realistically translate into patient-facing benefit, such as prevention strategies, better clinical decision-making, or pathways to curative approaches. Third is the requirement for preliminary data: applications must include preliminary and/or published evidence supporting the project concept and feasibility, and any unpublished preliminary findings should come from the PI or members of the research team, reinforcing that proposals should be grounded in real, relevant observations rather than purely speculative aims. Fourth is an emphasis on multidisciplinary collaboration, which is not mandatory but is clearly encouraged; teams can combine complementary scientific expertise and practical resources such as specialized assays, unique reagents, access to patient samples, clinical populations, or enabling services.

The program also offers a Partnering PI option to support genuine, team-based leadership. Under this structure, an application can name an Initiating PI and a Partnering PI, both of whom are expected to contribute substantially to the intellectual development and execution planning of the project, including core narrative elements and the statement of work. The Initiating PI typically handles most submission-related administrative responsibilities, but if funded, each PI is associated with an individual award within the recipient organization. Importantly, choosing the partnering PI option does not increase the direct cost limits; it is meant to strengthen collaborative science rather than expand the budget simply due to multiple PIs.

In practical terms, this opportunity is best viewed as supporting two lanes of progress in bone marrow failure research: FL1 backs well-supported research ideas that can deliver significant advances without running a clinical trial, while FL2 is specifically for teams ready to push one to three clearly identified therapeutic candidates through the IND-enabling data generation needed for FDA submission, again stopping short of funding the clinical trial itself. Both lanes prioritize high-impact questions, a clear line of sight to translation, credible preliminary data, and collaboration when it strengthens the project’s ability to deliver meaningful outcomes for people affected by bone marrow failure diseases.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Bone Marrow Failure Investigator-Initiated Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 04, 2022.
• Applicants must submit their applications by Sep 23, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 BMFRP IIRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: